JO2996B1 - مثبطات جانوس كيناز 3 غير متجانسة الحلقات - Google Patents
مثبطات جانوس كيناز 3 غير متجانسة الحلقاتInfo
- Publication number
- JO2996B1 JO2996B1 JOP/2006/0503A JOP20060503A JO2996B1 JO 2996 B1 JO2996 B1 JO 2996B1 JO P20060503 A JOP20060503 A JO P20060503A JO 2996 B1 JO2996 B1 JO 2996B1
- Authority
- JO
- Jordan
- Prior art keywords
- diseases
- inhibition activity
- present
- compound
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
يتعلق الاختراع الحالي بمركبات ذو فعالية ممتازة لتثبيط ( JAK3) يكون مفيدا في صورة مكون فعال لعامل للعلاج و / او الوقاية من الكثير من امراض المناعه العديدة شاملة امراض المناعة الذاتية، وامراض الالتهابات وامراض الحساسية ونتيجة للدراسات التي اجريت على مشتقات حلقية غير متجانسة مكثفة جديدة فقد وجد المخترعون ان المركب الذي له بنية بروابط متقاطعه يكون ذو فعالية تثبيط ممتازة ضد (JAK3) ثم قام المخترعون باستكمال الاختراع الحالي وبصيغه اخرى، فقد تم التحقق بان المركب وفقا للاختراع الحالي يكون ذو فعالية تثبيط ضد الـ (JAK3) وبالتالي فانه يكون مفيدا كمكون فعال لعامل للعلاج او للوقاية، من امراض تتسبب بواسطة انتقال اشارة لحركة خلوية غير مرغوب فيها ( على سبيل المثال) حدوث لفظ لعضو اثناء اجراء زرعه او غرسه، وامراض المناعه الذاتية، وحدوث التصلب المتعدد والتهاب المفصل الروماتويدي، والصدفية، الربو، والالتهاب الجلدي التحساسي، ومرض الزهايمر، ومرض التصلب العصيدي) او امراض تتسبب بواسطة انتقال اشارة لحركة خلوية شاذه "غير طبيعية" ( مثل السرطان، الليوكيميا "سرطان الدم")
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005378858 | 2005-12-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO2996B1 true JO2996B1 (ar) | 2016-09-05 |
Family
ID=37944023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2006/0503A JO2996B1 (ar) | 2005-12-28 | 2006-12-27 | مثبطات جانوس كيناز 3 غير متجانسة الحلقات |
Country Status (26)
Country | Link |
---|---|
US (2) | US7879844B2 (ar) |
EP (2) | EP2251341A1 (ar) |
JP (1) | JP5169829B2 (ar) |
KR (1) | KR101381092B1 (ar) |
CN (2) | CN102127078A (ar) |
AR (1) | AR058776A1 (ar) |
AU (1) | AU2006334044B2 (ar) |
BR (1) | BRPI0621873B8 (ar) |
CA (1) | CA2635850C (ar) |
CY (1) | CY1116393T1 (ar) |
DK (1) | DK1966200T3 (ar) |
ES (1) | ES2526202T3 (ar) |
HK (1) | HK1123303A1 (ar) |
IL (1) | IL192298A (ar) |
JO (1) | JO2996B1 (ar) |
MY (1) | MY148986A (ar) |
NO (1) | NO341555B1 (ar) |
NZ (1) | NZ569162A (ar) |
PL (1) | PL1966200T3 (ar) |
PT (1) | PT1966200E (ar) |
RU (1) | RU2434013C2 (ar) |
SI (1) | SI1966200T1 (ar) |
TW (1) | TWI389687B (ar) |
UA (1) | UA94437C2 (ar) |
WO (1) | WO2007077949A1 (ar) |
ZA (1) | ZA200805605B (ar) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2251341A1 (en) * | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
US8163767B2 (en) | 2005-07-14 | 2012-04-24 | Astellas Pharma Inc. | Heterocyclic Janus Kinase 3 inhibitors |
UA116187C2 (uk) | 2005-12-13 | 2018-02-26 | Інсайт Холдінгс Корпорейшн | ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ |
JPWO2008053652A1 (ja) | 2006-11-02 | 2010-02-25 | 塩野義製薬株式会社 | ヒドロキシアダマンタンアミンの製造方法 |
EP2123651A4 (en) * | 2007-01-12 | 2011-05-04 | Astellas Pharma Inc | CONDENSED PYRIDINE COMPOUND |
ES2714092T3 (es) | 2007-06-13 | 2019-05-27 | Incyte Holdings Corp | Uso de sales del inhibidor de quinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo |
WO2009007839A1 (en) | 2007-07-11 | 2009-01-15 | Pfizer Inc. | Pharmaceutical compositions and methods of treating dry eye disorders |
SI2074120T1 (sl) * | 2007-10-25 | 2010-06-30 | Exelixis Inc | Tropan spojine |
TW201612182A (en) | 2008-06-10 | 2016-04-01 | Abbvie Inc | Novel tricyclic compounds |
CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
DE102008052943A1 (de) | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
JPWO2010058846A1 (ja) * | 2008-11-21 | 2012-04-19 | アステラス製薬株式会社 | 4,6−ジアミノニコチンアミド化合物 |
EA021367B1 (ru) * | 2008-11-28 | 2015-06-30 | Кова Компани, Лтд. | Производное пиридин-3-карбоксамида |
UA106078C2 (uk) | 2009-05-22 | 2014-07-25 | Інсайт Корпорейшн | 3-[4-(7H-ПІРОЛО[2,3-d]ПІРИМІДИН-4-ІЛ)-1H-ПІРАЗОЛ-1-ІЛ]ОКТАН- АБО ГЕПТАННІТРИЛ ЯК JAK-ІНГІБІТОРИ |
TW201100429A (en) | 2009-05-22 | 2011-01-01 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
DK2440558T3 (en) | 2009-06-08 | 2015-07-06 | Takeda Pharmaceutical | Dihydropyrrolnaphthyridinon-relations as inhibitors of jak |
US9346809B2 (en) | 2009-07-08 | 2016-05-24 | Leo Pharma A/S | Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors |
FR2948370B1 (fr) | 2009-07-27 | 2013-04-05 | Sanofi Aventis | Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique |
FR2948369B1 (fr) | 2009-07-27 | 2013-04-12 | Sanofi Aventis | Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique |
WO2011028685A1 (en) | 2009-09-01 | 2011-03-10 | Incyte Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
WO2011045702A1 (en) | 2009-10-15 | 2011-04-21 | Pfizer Inc. | Pyrrolo[2,3-d] pyrimidine compounds |
ES2637588T3 (es) * | 2009-12-01 | 2017-10-13 | Abbvie Inc. | Nuevos compuestos tricíclicos |
CN102711470A (zh) * | 2009-12-01 | 2012-10-03 | 雅培制药有限公司 | 新的三环化合物 |
ES2461967T3 (es) | 2009-12-18 | 2014-05-21 | Pfizer Inc. | Compuestos de pirrolo[2,3-d]pirimidina |
CA2781578A1 (en) * | 2010-01-12 | 2011-07-21 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
TWI643857B (zh) | 2010-03-10 | 2018-12-11 | 英塞特公司 | 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物 |
US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
US8481541B2 (en) | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
EP2571881A1 (en) | 2010-05-20 | 2013-03-27 | F.Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives as syk and jak inhibitors |
PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
EP2592080B1 (en) | 2010-06-23 | 2016-02-24 | Astellas Pharma Inc. | Crystal of fused pyridine compound salt |
US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
JP5917545B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体 |
WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
US9233964B2 (en) | 2011-01-07 | 2016-01-12 | Leo Pharma A/S | Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof |
JP5936628B2 (ja) | 2011-02-18 | 2016-06-22 | ノバルティス・ファルマ・アクチェンゲゼルシャフトNovartis Pharma AG | mTOR/JAK阻害剤併用療法 |
EP2688890B1 (en) | 2011-03-22 | 2017-08-30 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
AR086983A1 (es) | 2011-06-20 | 2014-02-05 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
EP2741747A1 (en) | 2011-08-10 | 2014-06-18 | Novartis Pharma AG | JAK P13K/mTOR COMBINATION THERAPY |
IN2014MN00228A (ar) | 2011-08-12 | 2015-09-25 | Nissan Chemical Ind Ltd | |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
AU2012357296B2 (en) * | 2011-12-21 | 2017-04-13 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrrole six-membered heteroaryl ring derivative, preparation method therefor, and medicinal uses thereof |
WO2013116291A1 (en) * | 2012-01-30 | 2013-08-08 | Cephalon, Inc. | Imidazo [4, 5 - b] pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders |
UY34615A (es) * | 2012-02-10 | 2013-09-30 | Galapagos Nv | Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias. |
WO2013117649A1 (en) * | 2012-02-10 | 2013-08-15 | Galapagos Nv | Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases |
WO2013147135A1 (ja) * | 2012-03-30 | 2013-10-03 | アステラス製薬株式会社 | 放出制御医薬組成物 |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
GB201211021D0 (en) * | 2012-06-21 | 2012-08-01 | Cancer Rec Tech Ltd | Pharmaceutically active compounds |
EP2895172B1 (en) * | 2012-09-12 | 2019-02-06 | Rigel Pharmaceuticals, Inc. | Treatment for vitiligo |
JP2015529242A (ja) | 2012-09-21 | 2015-10-05 | アドヴィヌス セラピューティクス リミテッドAdvinus Therapeutics Limited | 置換された縮合三環式化合物、組成物およびその医薬用途 |
NZ748448A (en) | 2012-11-15 | 2019-12-20 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
TW201513861A (zh) * | 2013-01-17 | 2015-04-16 | Galapagos Nv | 用於治療退化性及發炎疾病之新穎化合物 |
US9475813B2 (en) | 2013-02-08 | 2016-10-25 | Nissan Chemical Industries, Ltd. | Tricyclic pyrrolopyridine compound, and JAK inhibitor |
TWI634121B (zh) | 2013-03-06 | 2018-09-01 | 英塞特控股公司 | 用於製備jak抑制劑之方法及中間物 |
WO2014146246A1 (en) * | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors |
JP5900702B2 (ja) * | 2013-03-29 | 2016-04-06 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
KR20220103810A (ko) | 2013-08-07 | 2022-07-22 | 인사이트 코포레이션 | Jak1 억제제용 지속 방출 복용 형태 |
KR101548492B1 (ko) | 2013-09-23 | 2015-09-01 | 건국대학교 산학협력단 | 야누스 키나아제 1 (Janus kinase 1)의 활성을 선택적으로 저해하는 4-아미노-7-아자인돌-5-카르복사마이드 유도체 |
TN2016000227A1 (fr) | 2013-12-05 | 2017-10-06 | Pfizer | Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides. |
HUE046150T2 (hu) * | 2014-04-22 | 2020-02-28 | Arqule Inc | Helyettesített imidazopiridinil-amino-piridin vegyületek sói és polimorf formái |
NZ725001A (en) | 2014-05-14 | 2021-08-27 | Nissan Chemical Ind Ltd | Tricyclic compound and jak inhibitor |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
WO2016047678A1 (ja) * | 2014-09-25 | 2016-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
KR102665765B1 (ko) * | 2015-07-20 | 2024-05-10 | 젠자임 코포레이션 | 콜로니 자극 인자-1 수용체(csf-1r) 저해제 |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
SG11201802990RA (en) | 2015-10-16 | 2018-05-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
US10730871B2 (en) * | 2016-01-28 | 2020-08-04 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
EP3481826B1 (en) | 2016-07-08 | 2021-11-03 | Rigel Pharmaceuticals, Inc. | Tyrosine kinase inhibitors |
HUE059274T2 (hu) * | 2016-12-16 | 2022-11-28 | Janssen Pharmaceutica Nv | Imidazo[4,5-d]pirrolo[2,3-b]piridin-származékok mint janus-kinázok inhibitorai |
JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
JP2018104412A (ja) * | 2016-12-22 | 2018-07-05 | 参天製薬株式会社 | 眼疾患の治療及び/又は予防剤 |
BR112019013287A2 (pt) | 2016-12-29 | 2019-12-24 | Hoffmann La Roche | compostos de pirazolopirimidina e métodos de uso dos mesmos |
KR101896568B1 (ko) | 2017-03-23 | 2018-09-10 | 재단법인 대구경북첨단의료산업진흥재단 | 피롤로-피리딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
WO2019057103A1 (zh) * | 2017-09-21 | 2019-03-28 | 上海华汇拓医药科技有限公司 | Jak激酶抑制剂及其制备方法和在医药领域的应用 |
GB201717260D0 (en) * | 2017-10-20 | 2017-12-06 | Galapagos Nv | Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders |
US10800775B2 (en) | 2017-11-03 | 2020-10-13 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same |
SG11202002947TA (en) * | 2017-11-03 | 2020-04-29 | Aclaris Therapeutics Inc | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
AU2019213665B2 (en) | 2018-01-30 | 2024-06-13 | Incyte Corporation | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
SI3773593T1 (sl) | 2018-03-30 | 2024-08-30 | Incyte Corporation | Zdravljenje hidradenitisa suppurative z zaviralci jak |
TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Jak激酶家族之小分子抑制劑 |
WO2020009946A1 (en) | 2018-07-02 | 2020-01-09 | Regents Of The University Of Minnesota | Therapeutic compounds and methods of use thereof |
EP3833350A4 (en) | 2018-08-10 | 2022-05-18 | Aclaris Therapeutics, Inc. | PYRROLOPYRIMIDINE TKI INHIBITORS |
JP7503054B2 (ja) * | 2018-10-16 | 2024-06-19 | ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド | Lrrk2の野生型および変異型のアザインドール阻害剤 |
KR20210134738A (ko) * | 2019-03-14 | 2021-11-10 | 상하이 시너지 파마슈티컬 사이언시스 코., 엘티디. | Jak 억제제 및 그 제조방법과 의약분야에서의 응용 |
SG11202108927UA (en) | 2019-05-02 | 2021-09-29 | Aclaris Therapeutics Inc | Substituted pyrrolopyridines as jak inhibitors |
KR102286372B1 (ko) * | 2019-05-27 | 2021-08-05 | 주식회사한국파마 | Jak 저해제 화합물, 및 이를 포함하는 의약 조성물 |
CN112174951A (zh) * | 2019-07-02 | 2021-01-05 | 深圳美莹基因科技有限公司 | 作为詹纳斯激酶1选择抑制剂的吡咯并[2,3-b]吡啶衍生物 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
JP2023533724A (ja) * | 2020-07-02 | 2023-08-04 | インサイト・コーポレイション | Jak2 v617f阻害剤としての三環式尿素化合物 |
WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
KR102551758B1 (ko) * | 2020-11-30 | 2023-07-05 | 주식회사한국파마 | 신규한 jak 특이 저해제 화합물, 및 이의 제조방법 |
WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
US11958861B2 (en) | 2021-02-25 | 2024-04-16 | Incyte Corporation | Spirocyclic lactams as JAK2 V617F inhibitors |
WO2023178285A1 (en) | 2022-03-17 | 2023-09-21 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
CN116283963A (zh) * | 2022-12-05 | 2023-06-23 | 西安美莹基因科技有限公司 | 一种高效詹纳斯激酶1选择性抑制剂 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR940702451A (ko) * | 1991-09-06 | 1994-08-20 | 고야 다다시 | 4-아미로(알킬)시클로헥산-1-카르복사미드 화합물 및 그 용도 |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
JP2002517396A (ja) | 1998-06-04 | 2002-06-18 | アボット・ラボラトリーズ | 細胞接着阻害抗炎症性化合物 |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
RS50087B (sr) | 1998-06-19 | 2009-01-22 | Pfizer Products Inc., | Pirolo (2,3-d) pirimidin jedinjenja |
US6946473B2 (en) * | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
EA006227B1 (ru) | 1999-12-10 | 2005-10-27 | Пфайзер Продактс Инк. | СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА |
CA2699568C (en) | 1999-12-24 | 2013-03-12 | Aventis Pharma Limited | Azaindoles |
US6335342B1 (en) | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
CA2413313C (en) | 2000-06-23 | 2011-06-14 | Mitsubishi Pharma Corporation | Antitumor effect potentiators |
CA2412560C (en) | 2000-06-26 | 2008-12-30 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents |
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
PL378246A1 (pl) | 2002-11-26 | 2006-03-20 | Pfizer Products Inc. | Sposób leczenia odrzucania przeszczepu |
JP2006514526A (ja) * | 2003-04-15 | 2006-04-27 | ハネウェル・インターナショナル・インコーポレーテッド | 電気アシストターボチャージャのための電気モータカートリッジ |
SE0301373D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
SE0301372D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
AR045595A1 (es) * | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
EP1689407A1 (en) | 2003-11-25 | 2006-08-16 | Pfizer Products Inc. | Method of treatment of atherosclerosis |
BRPI0417803A (pt) | 2003-12-17 | 2007-04-10 | Pfizer Prod Inc | método de tratamento de rejeição de transplantes |
MXPA06012663A (es) | 2004-05-03 | 2007-01-16 | Novartis Ag | Combinaciones que comprenden un agonista del receptor s1p y un inhibidor de quinasa jak3. |
MY179032A (en) * | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
UY29177A1 (es) * | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
MX2007006204A (es) | 2004-11-24 | 2007-06-20 | Novartis Ag | Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa. |
AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
EP2354140A1 (en) | 2005-05-20 | 2011-08-10 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
AU2006261993B2 (en) | 2005-06-22 | 2011-11-17 | Plexxikon, Inc. | Pyrrolo (2, 3-B) pyridine derivatives as protein kinase inhibitors |
EP2251341A1 (en) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
US8163767B2 (en) * | 2005-07-14 | 2012-04-24 | Astellas Pharma Inc. | Heterocyclic Janus Kinase 3 inhibitors |
EP2123651A4 (en) * | 2007-01-12 | 2011-05-04 | Astellas Pharma Inc | CONDENSED PYRIDINE COMPOUND |
-
2006
- 2006-07-13 EP EP10174035A patent/EP2251341A1/en not_active Withdrawn
- 2006-07-13 CN CN2010106153197A patent/CN102127078A/zh active Pending
- 2006-12-25 BR BRPI0621873A patent/BRPI0621873B8/pt active IP Right Grant
- 2006-12-25 DK DK06835198.0T patent/DK1966200T3/en active
- 2006-12-25 JP JP2008531051A patent/JP5169829B2/ja active Active
- 2006-12-25 PT PT68351980T patent/PT1966200E/pt unknown
- 2006-12-25 ES ES06835198.0T patent/ES2526202T3/es active Active
- 2006-12-25 UA UAA200809739A patent/UA94437C2/ru unknown
- 2006-12-25 WO PCT/JP2006/326327 patent/WO2007077949A1/en active Application Filing
- 2006-12-25 CN CN2006800499278A patent/CN101351466B/zh active Active
- 2006-12-25 EP EP06835198.0A patent/EP1966200B1/en active Active
- 2006-12-25 US US12/065,234 patent/US7879844B2/en active Active
- 2006-12-25 ZA ZA200805605A patent/ZA200805605B/xx unknown
- 2006-12-25 CA CA2635850A patent/CA2635850C/en active Active
- 2006-12-25 NZ NZ569162A patent/NZ569162A/en unknown
- 2006-12-25 SI SI200631879T patent/SI1966200T1/sl unknown
- 2006-12-25 RU RU2008130884/04A patent/RU2434013C2/ru active
- 2006-12-25 PL PL06835198T patent/PL1966200T3/pl unknown
- 2006-12-25 MY MYPI20082297A patent/MY148986A/en unknown
- 2006-12-25 AU AU2006334044A patent/AU2006334044B2/en active Active
- 2006-12-25 KR KR1020087018306A patent/KR101381092B1/ko active IP Right Grant
- 2006-12-27 JO JOP/2006/0503A patent/JO2996B1/ar active
- 2006-12-27 AR ARP060105828A patent/AR058776A1/es active IP Right Grant
- 2006-12-28 TW TW095149615A patent/TWI389687B/zh active
-
2008
- 2008-06-19 IL IL192298A patent/IL192298A/en active IP Right Grant
- 2008-07-25 NO NO20083308A patent/NO341555B1/no unknown
-
2009
- 2009-04-02 HK HK09103134.2A patent/HK1123303A1/xx unknown
-
2010
- 2010-10-28 US US12/914,475 patent/US20110039822A1/en not_active Abandoned
-
2015
- 2015-01-23 CY CY20151100074T patent/CY1116393T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO2996B1 (ar) | مثبطات جانوس كيناز 3 غير متجانسة الحلقات | |
CR20210357A (es) | Inhibidores de il-17a de imidazo[1,2-b]piridazina | |
WO2006094187A3 (en) | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | |
WO2004064723A3 (en) | Inhibitors and methods of use thereof | |
WO2004078144A3 (en) | Diphenylethylene compounds and uses thereof | |
DE60316542D1 (de) | 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen | |
WO2004094388A3 (en) | Indazole derivatives as jnk inhibitors | |
EA200001188A1 (ru) | ПИРРОЛО[2,3-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ | |
MXPA03009846A (es) | Derivados de triazol inhibidores de cinasa y usos de los mismos. | |
CA2369504A1 (en) | Pyrazole compositions useful as inhibitors of erk | |
DE60238620D1 (de) | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung | |
WO2008045393A3 (en) | Imidazo- and triazolo-pyridine compounds and methods of use therof | |
HK1052934A1 (en) | Isoxazoles and their use as inhibitors of erk | |
MA29797B1 (fr) | DERIVES DE LA PYRROLOPYRIMIDINE INHIBITEURS DE LA Syk | |
WO2006028963A3 (en) | Substituted heterocyclic compounds and uses thereof | |
WO2019226213A3 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
WO2007124181A3 (en) | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use | |
MX2007002525A (es) | Compuestos de difeniletileno y usos de los mismos. | |
WO2004100890A3 (en) | Rage g82s-related methods and compositions for treating inflammatory disorders | |
DK0980374T3 (da) | Phosphodiesterase 4-inhiberende diazepinoindoloner. | |
MX2023015436A (es) | Inhibidores de cdk2 y metodos de uso de los mismos. | |
WO2024026486A3 (en) | Cdk2 inhibitors and methods of using the same | |
WO2024026481A3 (en) | Cdk2 inhibitors and methods of using the same | |
WO2002060375A3 (en) | Diphenyl ether derivatives and their uses as heparanase inhibitors | |
ATE423102T1 (de) | 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer |